BioLineRx BLRX Stock
BioLineRx Price Chart
BioLineRx BLRX Financial and Trading Overview
| BioLineRx stock price | 2.21 USD |
| Previous Close | 2.3 USD |
| Open | 2.3 USD |
| Bid | 2.2 USD x 100 |
| Ask | 2.31 USD x 100 |
| Day's Range | 2.28 - 2.4 USD |
| 52 Week Range | 2.15 - 4.56 USD |
| Volume | 13.88K USD |
| Avg. Volume | 19.23K USD |
| Market Cap | 11.35M USD |
| Beta (5Y Monthly) | 0.702 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22 USD |
BLRX Valuation Measures
| Enterprise Value | 7.85M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.9047619 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 8.153975 |
| Price/Book (mrq) | 0.76 |
| Enterprise Value/Revenue | 5.637 |
| Enterprise Value/EBITDA | -0.648 |
Trading Information
BioLineRx Stock Price History
| Beta (5Y Monthly) | 0.702 |
| 52-Week Change | -47.74% |
| S&P500 52-Week Change | 15.77% |
| 52 Week High | 4.56 USD |
| 52 Week Low | 2.15 USD |
| 50-Day Moving Average | 2.64 USD |
| 200-Day Moving Average | 2.82 USD |
BLRX Share Statistics
| Avg. Volume (3 month) | 19.23K USD |
| Avg. Daily Volume (10-Days) | 14.07K USD |
| Shares Outstanding | 4.98M |
| Float | 4.14M |
| Short Ratio | 5.24 |
| % Held by Insiders | 3.42% |
| % Held by Institutions | 1.33% |
| Shares Short | 145.8K |
| Short % of Float | 3.00% |
| Short % of Shares Outstanding | 3.00% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:40 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1215.30% |
| Gross Margin | 80.02% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -19.82% |
| Return on Equity (ttm) | -55.27% |
Income Statement
| Revenue (ttm) | 1.39M USD |
| Revenue Per Share (ttm) | 0.6 USD |
| Quarterly Revenue Growth (yoy) | -3.30% |
| Gross Profit (ttm) | 1.11M USD |
| EBITDA | -12118000 USD |
| Net Income Avi to Common (ttm) | -6989000 USD |
| Diluted EPS (ttm) | 0 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 13.08M USD |
| Total Cash Per Share (mrq) | 2.99 USD |
| Total Debt (mrq) | 7.94M USD |
| Total Debt/Equity (mrq) | 47.78 USD |
| Current Ratio (mrq) | 1.195 |
| Book Value Per Share (mrq) | 3 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -10803000 USD |
| Levered Free Cash Flow (ttm) | -8852375 USD |
Profile of BioLineRx
| Country | United States |
| State | N/A |
| City | Hevel Modi'in |
| Address | Modi’in Technology Park |
| ZIP | 7177871 |
| Phone | 972 8 642 9100 |
| Website | https://www.biolinerx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 20 |
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Q&A For BioLineRx Stock
What is a current BLRX stock price?
BioLineRx BLRX stock price today per share is 2.21 USD.
How to purchase BioLineRx stock?
You can buy BLRX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioLineRx?
The stock symbol or ticker of BioLineRx is BLRX.
Which industry does the BioLineRx company belong to?
The BioLineRx industry is Biotechnology.
How many shares does BioLineRx have in circulation?
The max supply of BioLineRx shares is 4.98M.
What is BioLineRx Price to Earnings Ratio (PE Ratio)?
BioLineRx PE Ratio is now.
What was BioLineRx earnings per share over the trailing 12 months (TTM)?
BioLineRx EPS is 0 USD over the trailing 12 months.
Which sector does the BioLineRx company belong to?
The BioLineRx sector is Healthcare.
BioLineRx BLRX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
27357.45 USD — |
+0.6
|
4.05B USD — | 27254.03 USD — | 27376.85 USD — | — - | 4.05B USD — |
|
US Tech Capital Market Composite
RCMP
US
|
125.02 USD — |
+0.74
|
— — | 124.02 USD — | 125.07 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1317.13 USD — |
+2.44
|
— — | 1286.21 USD — | 1319.34 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
33790.98 USD — |
+0.59
|
— — | 33667.91 USD — | 33819.63 USD — | — - | — — |
- {{ link.label }} {{link}}
